PLA2G2A and cutaneous leishmaniasis: So, a PLA2 from B. jararacussu venom encapsulated in liposomes displays therapeutic effectiveness comparable to that of known antiparasitic Glucantime in a cutaneous leishmaniasis mouse model [70].